
Global Biologics Market Research Report: Forecast (2025-2030)
Biologics Market - By Therapeutic Application (Oncology, Infectious Disease, Autoimmune Disease, Diabetes, Cardiovascular Diseases, Others (Inflammatory Bowel Diseases, Respiratory...Disorders, Ophthalmic Disorders, etc.)), By Drug Class (Recombinant Proteins, [Hormones, Cytokines], Monoclonal Antibodies, Blood & Blood Components, Cellular & Gene Therapy, Vaccines, Others), By Source (Microbes, Humans, Others (Rodents, Plants, etc.)), Others Read more
- Healthcare
- Apr 2024
- 197
- PDF, Excel, PPT
Market Definition
Biologics are medications that are either sourced from living organisms or composed of elements from living organisms and are commonly found in the form of genetically engineered proteins. These pharmaceuticals play a crucial role in addressing chronic ailments such as cancer, neurology issues, cardiovascular disorders, etc.
Market Insights & Analysis: Global Biologics Market (2025-30):
The Global Biologics Market size was valued at USD 412 Billion in 2024 and is projected to reach USD 612 Billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.25% during the forecast period, i.e., 2025-2030. The surging expenditures in healthcare, a hike in the sedentary lifestyles of individuals, and the rising number of chronic disease patients are some of the highlighting aspects promoting the industry growth. Other factors driving the demand for biologics across the global scale include enhanced usage of monoclonal antibodies for disease treatment, innovation & advancement in the healthcare & biotechnology sectors, and to cure diseases, including anemia, rheumatoid arthritis, osteoporosis, Alzheimer's, etc. Also, diseases like cancer and autoimmune disorders, which pose significant healthcare challenges, underscore the importance of targeted therapeutic interventions, and hence, have been driving the need for biologics over the historical years.
Report Coverage | Details |
---|---|
Historical Years | 2020-23 |
Base Years
|
2024
|
Forecast Years
|
2025-30
|
Market Value in 2024 | USD 412 Billion |
Market Value in 2030 | USD 612 Billion |
CAGR (2025-30) | 8.25% |
Leading Region | North America |
Top Key Players | Bristol-Myers Squibb, Pfizer, Sanofi, Janssen Biotech, Inc., Bayer AG, Merck & Co., Amgen Inc., Abbott GmbH, Novartis, AstraZeneca Plc, GlaxoSmithKline Biologicals, Moderna, Inc., Ferring Pharmaceuticals Inc., Aimmune Therapeutics, Inc., F. Hoffman La Roche, and Others |
Key Report Highlights |
|
*Boost strategic growth with in-depth market analysis - Get a free sample preview today!
Moreover, the incessant surge in the old age population is notably augmenting the demand for biologics such as erythropoietin (EPO), denosumab, teriparatide, etc. Furthermore, fastened regulatory approvals from the governments in different countries were also contributing to the growth of the Biologics market. For instance:
- In 2023, the FDA sanctioned 35 fresh biologics as part of their documented progress toward decreased regulation and expansion of gene & cell therapy offerings. During H1-22, The Center for Drug Evaluation and Research approved an additional 10 innovative biologics medicines compared to last year's figures.
Hence, with improved regulatory approvals, the launch of new biologics in the market has accelerated. Moreover, as Biologics offers tailored solutions targeting specific cells or molecules responsible for diseases, it not only enhances treatment efficacy but also mitigates adverse effects significantly, thus its adoption is anticipated to boost in the coming years as well.

Global Biologics Market Driver:
Increasing Inclination Towards Gene Therapy & Cellular Therapy to Boost the Market Growth – Due to their ability to repair or substitute damaged tissues, gene and cellular treatments have experienced considerable growth in adoption over the historical years. Moreover, the rising investments in research & development of cell and gene therapies have been further bolstering their adoption, owing to the improved efficacy of new drugs. Additionally, there has been increased funding and investments for R&D purposes of cell and gene therapies by companies like Ori Biotech, AstraZeneca Plc, GlaxoSmithKline Biologicals, etc., for the launch of innovative products.
Thus, with enhanced investment, the process of pre-commercialization and market launch has been accelerated, which has been contributing to the market growth. Also, over the historical years, the approvals of these medicines have been accelerated by government organizations like the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), etc. Consequently, as approvals for cell and gene therapies would accelerate in the coming years, it would create an opportunity for their enhanced adoption in the coming years as well.
Global Biologics Market Opportunity:
Biotechnology Techniques ‘CRISPR-Cas9’ to Revolutionize Biologics Drug Development in Future Years – The adoption of CRISPR-Cas9 technology among the Biologics drugs offering companies for research & development purposes possesses significant opportunities for market growth. This technology holds immense potential for developing next-generation biologics by correcting genetic defects or enhancing therapeutic efficacy, thus boosting the development of biologics drugs on a large scale. For instance:
- In 2023, the FDA approved the first gene therapies, i.e., Casgevy and Lyfgenia, to treat Sickle Cell Disease (SCD). Casgevy is the first FDA-approved therapy using CRISPR/Cas9 to edit patients' blood stem cells.
Hence, the adoption of CRISPR-Cas9 technology allows companies to effectively develop biologics, like gene therapies, thus holding immense potential for the growth of the Biologics Market in the coming years.
Global Biologics Market Challenge:
Enhanced Cost for Accessing Biologics Source to Hinder Industry Expansion – The ever-increasing cost expenses tied to acquiring biologics sources have been presenting a multifaceted challenge to healthcare ecosystems & pharmaceutical enterprises. The complex and costly nature of biologics has been compounded by regulatory frameworks like the FDA & EMA, enabling strict criteria for the approval & commercialization of biologic products. These criteria encompass thorough testing and documentation to prove their effectiveness, safety, and quality.
As a result, the process of developing biologics has been prolonged, and manufacturers have been facing increased expenses owing to regulatory factors. Thus, the companies had to uplift the selling cost of biologics, and the high cost of these drugs has been affecting the large-scale adoption globally. Consequently, Global Biologics has been affected negatively due to the rising costs of the products during the historical years, which is anticipated to prevail in the coming years as well.
Global Biologics Market Trend:
Rising Demand for Personalized Medicine Augmenting the Biologics Market Growth – In recent years, there has been a significant increase in the demand for personalized medicines among patients and healthcare professionals across the globe, as they meet the specific needs of an individual. Hence, as biologics can be modified and engineered to fit these requirements, it has been used largely by pharmaceutical companies for the development of personalized medicines, which have been offering more effective & patient-centric treatment options. Thus, the demand for personalized medicine has emerged as a new trend in the Global Biologics Market in recent years.
Moreover, in addition to the development of precision medicines, biologics also play a major role in the identification and development of diagnostic tools such as biomarkers, which allow disease diagnosis. Consequently, with advancements in the usage of biologics for the development of diagnostic methods and precision medicines, it is anticipated to contribute to the market growth in the coming years as well.
Global Biologics Market (2025-30): Segmentation Analysis
The Global Biologics Market study by MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2025-2030 at the global level. In accordance to the analysis, the market has been further classified as:
Based on Drug Class:
- Recombinant Proteins
- Hormones
- Cytokines
- Monoclonal Antibodies (mAbs)
- Blood & Blood Components
- Cellular & Gene Therapy
- Vaccines
- Others
Monoclonal Antibodies (mAbs) have been gaining traction because of their capability to treat illnesses such as cancers, autoimmune issues, and infections. Advances in antibody engineering & hybridoma technologies have led to the creation of precise and powerful mAbs, therefore contributing to the growth of the Global Biologics Market.
Also, over the past few years, the increasing prevalence of diseases such as rheumatoid arthritis (RA), as well as certain cancers, viral infections, gastrointestinal diseases, and more, have generated the demand for monoclonal antibodies since they have been widely used in several therapeutic areas to cure these diseases. Therefore, there has been an increase in the market share of monoclonal antibodies in the Biologics Market during the forecast period.
Based on Therapeutic Application:
- Oncology
- Infectious Disease
- Autoimmune Disease
- Diabetes
- Cardiovascular Diseases
- Others (Inflammatory Bowel Diseases, Respiratory Disorders, Ophthalmic Disorders, etc.)
The Oncology segment witnessed substantial market growth during historical years. Oncology has been one of the largest markets for biologics due to the high unmet demand for effective cancer treatments. Biologics such as monoclonal antibodies and immune checkpoint inhibitors have revolutionized cancer treatment by targeting specific proteins or cells.
Also, with the surging need to treat cancer and improve global mortality burdens, governments of various countries, including the US, Canada, India, China, etc., are increasingly focusing on boosting investments in oncology drug development, driving the demand for biologics production & distribution globally.
Global Biologics Market (2025-30): Regional Projection
Geographically, the Global Biologics Market expands across:
- North America
- South America
- Europe
- The Middle East & Africa
- Asia-Pacific
North America held the major share of the Global Biologics Market. The dominance of North America has been attributed to its sturdy healthcare infrastructure & great investments in biopharmaceutical studies. Also, as North America hosts a significant number of biopharmaceutical companies and research establishments that foster innovation, it has become a promising location for future market development.
Furthermore, the market growth has also been influenced by the presence of a favorable regulatory environment, which fosters accelerated approvals for biologics. Also, the escalating prevalence of various diseases, coupled with a growing awareness among affected individuals and their willingness to explore novel treatment modalities, is expected to significantly augment the demand for biologics in North America during 2025-30.
Global Biologics Industry Recent Developments
- 2023: Amgen announced the completion of the acquisition of biologics market player, Horizon Therapeutics, which is aligned with its vision for the development of drugs for patients with rare diseases.
- 2023: AstraZeneca Plc. announced that the Ministry of Health, Labour, and Welfare in Japan approved the extended utilization of Soliris (eculizumab) biologics in the treatment of pediatric patients laid low with generalized myasthenia gravis, particularly those who have no longer responded nicely to different treatment options.
Gain a Competitive Edge with Our Global Biologics Market Report
- Global Biologics Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
- This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
- Global Biologics Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.
*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.
Frequently Asked Questions
- Market Segmentation
- Introduction
- Product Definition
- Research Process
- Assumptions
- Executive Summary
- Global Biologics Market Clinical Trial Analysis
- Global Biologics Guidelines by Government Organizations
- World Health Organisation (WHO)
- European Medicines Agency (EMA)
- Food and Drug Administration (FDA)
- Global Biologics Market Patent Analysis
- Global Biologics Market Trends & Developments
- Global Biologics Market Dynamics
- Growth Drivers
- Challenges
- Global Biologics Market Hotspot & Opportunities
- Global Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application
- Oncology- Market Size & Forecast 2020-2030, (USD Million)
- Infectious Disease- Market Size & Forecast 2020-2030, (USD Million)
- Autoimmune Disease- Market Size & Forecast 2020-2030, (USD Million)
- Diabetes- Market Size & Forecast 2020-2030, (USD Million)
- Cardiovascular Diseases- Market Size & Forecast 2020-2030, (USD Million)
- Others (Inflammatory Bowel Diseases, Respiratory Disorders, Ophthalmic Disorders, etc.)- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class
- Recombinant Proteins- Market Size & Forecast 2020-2030, (USD Million)
- Hormones- Market Size & Forecast 2020-2030, (USD Million)
- Cytokines- Market Size & Forecast 2020-2030, (USD Million)
- Monoclonal Antibodies- Market Size & Forecast 2020-2030, (USD Million)
- Blood & Blood Components- Market Size & Forecast 2020-2030, (USD Million)
- Cellular & Gene Therapy- Market Size & Forecast 2020-2030, (USD Million)
- Vaccines- Market Size & Forecast 2020-2030, (USD Million)
- Others- Market Size & Forecast 2020-2030, (USD Million)
- Recombinant Proteins- Market Size & Forecast 2020-2030, (USD Million)
- By Source
- Microbes- Market Size & Forecast 2020-2030, (USD Million)
- Humans- Market Size & Forecast 2020-2030, (USD Million)
- Others (Rodents, Plants, etc.)- Market Size & Forecast 2020-2030, (USD Million)
- By Region
- North America
- South America
- Europe
- The Middle East & Africa
- Asia-Pacific
- By Company
- Competition Characteristics
- Revenue Shares & Analysis
- By Therapeutic Application
- Market Size & Analysis
- North America Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- By Source- Market Size & Forecast 2020-2030, (USD Million)
- By Country Market Size & Forecast 2020-2030, (USD Million)
- The US
- Canada
- Mexico
- The United States Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Canada Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Mexico Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Market Size & Analysis
- South America Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- By Source- Market Size & Forecast 2020-2030, (USD Million)
- By Country- Market Size & Forecast 2020-2030, (USD Million)
- Brazil
- Rest of South America
- Brazil Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Market Size & Analysis
- Europe Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- By Source- Market Size & Forecast 2020-2030, (USD Million)
- By Country- Market Size & Forecast 2020-2030, (USD Million)
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Germany Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- The UK Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- France Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Italy Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Spain Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Market Size & Analysis
- Middle East & Africa Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- By Source- Market Size & Forecast 2020-2030, (USD Million)
- By Country- Market Size & Forecast 2020-2030, (USD Million)
- The UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- The UAE Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Saudi Arabia Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- South Africa Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Market Size & Analysis
- Asia-Pacific Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- By Source- Market Size & Forecast 2020-2030, (USD Million)
- By Country- Market Size & Forecast 2020-2030, (USD Million)
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- China Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- India Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Japan Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- South Korea Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Australia Biologics Market Outlook, 2020-2030F
- Market Size & Analysis
- By Revenues (USD Million)
- Market Share & Analysis
- By Therapeutic Application- Market Size & Forecast 2020-2030, (USD Million)
- By Drug Class- Market Size & Forecast 2020-2030, (USD Million)
- Market Size & Analysis
- Market Size & Analysis
- Global Biologics Market Key Strategic Imperatives for Success & Growth
- Competition Outlook
- Company Profiles
- Bristol-Myers Squibb
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Pfizer
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Sanofi
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Janssen Biotech, Inc.
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Bayer AG
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Merck & Co.
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Amgen Inc.
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Abbott GmbH
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Novartis
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- AstraZeneca Plc
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- GlaxoSmithKline Biologicals
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Moderna, Inc.
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Ferring Pharmaceuticals Inc.
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Aimmune Therapeutics, Inc.
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- F. Hoffman La Roche
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Others
- Bristol-Myers Squibb
- Company Profiles
- Disclaimer
